🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Cadonilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  2. Calquence 100 mg film-coated tablets, ACALABRUTINIB

    Ningbo Cancer Hospital

    Disseminated large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  3. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  4. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adrenal Cortical Carcinoma

    phase 2 small molecule active

    1 trial

  5. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Neoplasms

    phase 2 small molecule active

    1 trial

  6. Camrelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  7. Camrelizumab

    The First People's Hospital of Lianyungang

    Locally Advanced or Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. Camrelizumab

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  9. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  11. Camrelizumab

    The First People's Hospital of Lianyungang

    Lung Cancer, Nonsmall Cell

    phase 2 small molecule active

    1 trial

  12. Camrelizumab

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 small molecule active

    1 trial

  13. Camrelizumab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  14. Camrelizumab plus apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  15. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  16. Cangpo Liujun Prescription

    The First People's Hospital of Lianyungang

    Cancer-Related Fatigue

    phase 2 small molecule active

    1 trial

  17. Capecitabine

    The First People's Hospital of Lianyungang

    Biliary Carcinoma

    phase 2 small molecule active

    1 trial

  18. Capecitabine Accord 500 mg film-coated tablets

    Ningbo Cancer Hospital

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  19. Capecitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasms

    phase 2 small molecule terminated

    1 trial

  20. Capecitabine-Oxaliplatin-Irinotecan Combination

    The First People's Hospital of Lianyungang

    Unresectable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  21. Carbon Nanoparticle Iron Suspension for Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HNSCC

    phase 2 small molecule active

    1 trial

  22. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etomedac 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung

    Ningbo Cancer Hospital

    Stage IIA/B seminoma

    phase 2 small molecule active

    1 trial

  23. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herst

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial

  24. Carboplatin

    Children's Hospital of Fudan University

    Desmoplastic/Nodular Medulloblastoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources